Home » Stocks » Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc. (LCTX)

Stock Price: $1.25 USD 0.01 (0.81%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 187.48M
Revenue (ttm) 2.71M
Net Income (ttm) -35.91M
Shares Out 149.98M
EPS (ttm) -0.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $1.25
Previous Close $1.24
Change ($) 0.01
Change (%) 0.81%
Day's Open 1.28
Day's Range 1.22 - 1.29
Day's Volume 378,672
52-Week Range 0.53 - 1.67

More Stats

Market Cap 187.48M
Enterprise Value 147.43M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 149.98M
Float 149.21M
EPS (basic) -0.24
EPS (diluted) -0.37
FCF / Share -0.15
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 7.26M
Short Ratio 10.21
Short % of Float 4.87%
Beta 2.13
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 69.23
PB Ratio 1.64
Revenue 2.71M
Operating Income -29.13M
Net Income -35.91M
Free Cash Flow -22.24M
Net Cash 40.04M
Net Cash / Share 0.27
Gross Margin 114.59%
Operating Margin -1,075.85%
Profit Margin -1,326.00%
FCF Margin -821.31%
ROA -13.14%
ROE -31.40%
ROIC -72.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 3
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$4.67*
(273.60% upside)
Low
3.00
Current: $1.25
High
7.00
Target: 4.67
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue3.524.993.465.927.045.244.433.924.433.71
Revenue Growth-29.53%44.25%-41.62%-15.82%34.17%18.27%13.25%-11.7%19.58%-
Gross Profit3.104.693.295.575.934.413.643.484.353.68
Operating Income-38.88-41.80-38.90-58.97-65.81-50.68-55.99-25.32-18.69-9.85
Net Income-11.71-45.99-19.9833.57-46.99-36.41-43.88-21.43-16.52-11.18
Shares Outstanding14612711497.3279.7166.4754.2349.2147.0540.27
Earnings Per Share-0.08-0.36-0.170.34-0.59-0.55-0.81-0.44-0.35-0.28
Operating Cash Flow-31.95-30.88-30.52-42.33-44.54-38.85-29.51-19.68-13.59-7.73
Capital Expenditures-0.36-1.42-1.13-2.53-5.33-0.69-2.25-0.40-0.96-0.21
Free Cash Flow-32.31-32.30-31.64-44.85-49.88-39.55-31.76-20.08-14.55-7.95
Cash & Equivalents54.3330.7438.1822.7242.9829.495.624.4122.2733.38
Total Debt5.172.271.533.985.100.53----
Net Cash / Debt49.1628.4836.6418.7337.8828.965.624.4122.2733.38
Assets12510217314394.6674.9057.7329.7545.8353.27
Liabilities14.239.418.9812.0618.2112.1815.475.454.373.85
Book Value11393.8416311825.8236.4614.809.5828.6538.17
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Lineage Cell Therapeutics, Inc.
Country United States
Employees 50
CEO Brian M. Culley

Stock Information

Ticker Symbol LCTX
Stock Exchange NYSE American
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSEAMERICAN: LCTX

Description

Lineage Cell Therapeutics, a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in clinical trial for the treatment of HIV-associated facial lipoatrophy; HyStem, a biomaterial used for cell replacement and retention; and Premvia, a Hystem Hydrogel product, as well as develops bone grafting products for the orthopedic diseases and injuries. In addition, the company offers various therapeutic products for the treatment of oncology, neurological diseases and disorders, blood and vascular system diseases and disorders, and blood plasma volume expansion, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.